SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-23-005344
Filing Date
2023-11-06
Accepted
2023-11-06 16:55:23
Documents
2

Document Format Files

Seq Description Document Type Size
1 STOKE THERAPEUTICS, INC. p23-2664sc13g.htm SC 13G 61254
2 JOINT FILING AGREEMENT p23-2664exhibit99.htm EX-99.1 4381
  Complete submission text file 0000902664-23-005344.txt   67250
Mailing Address 45 WIGGINS AVENUE BEDFORD MA 01730
Business Address 45 WIGGINS AVENUE BEDFORD MA 01730 781-430-8200
Stoke Therapeutics, Inc. (Subject) CIK: 0001623526 (see all company filings)

IRS No.: 471144582 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-91051 | Film No.: 231380585
SIC: 2834 Pharmaceutical Preparations

Mailing Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607
Business Address 151 CALLE DE SAN FRANCISCO SUITE 200 PMB 1237 SAN JUAN PR 00901-1607 703-963-7214
Lynx1 Capital Management LP (Filed by) CIK: 0001910456 (see all company filings)

IRS No.: 851134656 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G